Vitiligo is a chronic autoimmune disease that presents as depigmenting the skin. It affects more than 1.5 million people in the U.S., according to an Incyte press release.
After 52 weeks, phase 3 trials for topical cream Opzelura showed improvements from the baseline in the facial Vitiligo Area Sourcing Index among 50 percent of the study participants.
Opzelura, a JAK inhibitor, is approved for ages 12 and up for nonsegmental vitiligo and mild to moderate eczema.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
